Commenting on the news, Ronan O’Caoimh, CEO, said, Following the successful completion of our CLIA trials in four independent sites in the USA, I am delighted to announce the submission of our TRI-stat CLIA application to the FDA. The test will allow us to address a market which continues to grow significantly each year due to the need for decentralisation of testing to doctors’ offices, the recommendations from the American Diabetes Association and the International Diabetes Federation for more frequent patient monitoring and the ongoing increase in the prevalence of diabetes. We will be showcasing the product at the AACC Clinical Lab Expo in Chicago on 21-23 July, 2009.
